Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation
Mohamed Rahmani, Mandy Mayo Aust, Elisa Hawkins, Rebecca E. Parker, Masey Ross, Maciej Kmieciak, Leonid Borisovich Reshko, Kathryn A. Rizzo, Catherine I. Dumur, Andrea Ferreira-Gonzalez, Steven Grant
Research output: Contribution to journal › Article › peer-review
29Scopus
citations
Fingerprint
Dive into the research topics of 'Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation'. Together they form a unique fingerprint.